STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 957 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
STAA'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
STAAR Surgical Co'in en son EPS'si $0.23 olup, $-0.06 beklentilerini vurmak.
STAAR Surgical Co STAA'ün son çeyrekteki geliri nasıl performans gösterdi?
STAAR Surgical Co'in son çeyrek geliri $0.23
STAAR Surgical Co'in gelir tahmini nedir?
12 Wall Street analistine göre, STAAR Surgical Co'in gelir tahmini $94.71M ile $67.68M arasında değişmektedir.
STAAR Surgical Co'in kazanç kalite puanı nedir?
STAAR Surgical Co'in kazanç kalite puanı B+/50.620064'dir. Puan, karlılık, büyüme, nakit üretimi ve sermaye tahsisi ile kaldıraç olmak üzere dört boyuta dayanır.
STAAR Surgical Co kazançlarını ne zaman rapor eder?
STAAR Surgical Co'in bir sonraki kazanç raporu 2026-08-11'te bekleniyor